Rescue therapy with tacrolimus (FK 506) in renal transplant recipients--a Scandinavian multicenter analysis

Transplant International : Official Journal of the European Society for Organ Transplantation
M FelldinN H Persson

Abstract

All renal allograft recipients (n = 32) in Sweden and Norway who were converted from cyclosporin (CyA)-based immunosuppression to FK 506 (tacrolimus) between October 1992 and June 1995 were analyzed retrospectively. The reasons for conversion were acute refractory rejection (n = 21), chronic rejection (n = 4), and suspected CyA toxicity (n = 6); one patient was converted for psychological reasons. The mean time from transplantation to conversion was 29 (range 1-243) weeks and there was a mean follow-up of 46 (2-143) weeks. Overall graft survival was 59%, with graft survival 52% in patients converted because of acute rejection, 50% in patients converted because of chronic rejection, and 83% in patients converted because of CyA toxicity. There was no significant correlation between preconversion serum creatinine and outcome. Seventy-two percent of the patients had significant side effects during FK 506 treatment, the most frequent ones being neurological and gastrointestinal symptoms. These improved after dose reduction. Two patients became overimmunosuppressed and developed lymphoma. One patient died of the primary kidney disease, hemolytic uraemic syndrome. We conclude that FK 506 therapy is able to salvage kidneys with acute r...Continue Reading

Citations

Aug 15, 2002·Transplantation Proceedings·K BuddeH-H Neumayer
Jun 24, 1998·Transplantation Proceedings·V KliemR Brunkhorst
Jun 24, 1998·Transplantation Proceedings·M L JordanT E Starzl
Sep 2, 1998·Transplantation Proceedings·P A Keown, D R Primmett
Jun 18, 1999·Transplantation Proceedings·P A Keown
Nov 27, 1999·Transplantation Proceedings·M L JordanT E Starzl
Dec 10, 2003·Plastic and Reconstructive Surgery·Roberta K YangSusan E Mackinnon
Jan 17, 2003·Paediatric Drugs·Dominique DebrayChristophe Chardot
Sep 20, 2018·Biotechnology and Bioengineering·Pratima LabrooJayant Agarwal
May 22, 2021·Experimental and Clinical Transplantation : Official Journal of the Middle East Society for Organ Transplantation·Ozlem Tugce Cilingir-KayaSemra Karsidag

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Transplant International : Official Journal of the European Society for Organ Transplantation
M ShiraishiY Muto
Pediatric Nephrology : Journal of the International Pediatric Nephrology Association
J LemireV Reznik
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
R A Koene, L B Hilbrands
© 2022 Meta ULC. All rights reserved